Article
The significance of FOXP1 in diffuse large B-cell lymphoma.
Leukemia & lymphoma - 1 May 2017
Gascoyne Duncan M, Banham Alison H
Abstract excerpt
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of mature B-cell lymphoma. While the majority of patients are cured with immunochemotherapy incorporating the anti-CD20 monoclonal antibody rituximab (R-CHOP), relapsed and refractory patients still have a dismal prognosis. DLBCL subtypes including an aggressive activated B-cell-like (ABC) and a more favorable prognosis germinal center-like (GCB)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
